Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma ...

JCO is the primary forum of scientific discourse for the American Society of Clinical Oncology (ASCO). Published three times a month, JCO is the foremost peer-reviewed journal focusing on clinical ...

To advance the call to action to optimize dosage of anticancer agents, FDA and ASCO cosponsored two multistakeholder workshops, Getting the Dose Right: Optimizing Dose Selection Strategies in Oncology ...

In 2022, ASCO launched living clinical practice guidelines for systemic therapy for patients with stage IV non–small cell lung cancer (NSCLC) with 1 and without 2 driver alterations. Both have been ...

We aimed to assess whether lung cancer (LC) screening with low-dose computed tomography (LDCT) is cost effective in a high-risk population (current or former smokers—who stopped smoking within <15 ...

Systematic mediastinal lymph node dissection (LND) or sampling is currently recommended for patients with early-stage non–small cell lung cancer. We aimed to investigate whether no mediastinal LND was ...

In the article that accompanies this editorial, Yin et al 12 present the early phase development and validation of a fragmentomics-based biomarker for the earlier detection of pancreatic cancer. While ...

Early-phase clinical trials (EPCTs) have been increasingly adopted as the pivotal trial to support US Food and Drug Administration (FDA) approval of novel anticancer drugs. Among EPCT designs, ...

In this JCO Article Insights episode, Michael Hughes summarizes “ International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk ...

As an oncologist trained in a program with a strong emphasis on shared decision making between physician and patient, I approach such situations with curiosity. I consider optimal shared decision ...

PURPOSEThe surveillance protocol for early-stage non–small cell lung cancer (NSCLC) is not contingent upon individualized risk factors for recurrence. This study aimed to use comprehensive data from ...

Divarasib (GDC-6036), an oral, highly potent and selective next-generation KRAS G12C inhibitor, has demonstrated a manageable safety profile and promising antitumor activity in patients with advanced ...